CARLSBAD, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CB Therapeutics (the “Company”), a biotechnology and precision fermentation company focused on using cellular agriculture to produce...
CARLSBAD, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- CB Therapeutics (the “Company”), a biosynthesis company focused on creating ethically-produced, environmentally-friendly products for human health, is celebrating a move to an expanded laboratory, which will serve to increase its research compound production footprint.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr. Brian Barnett to its newly formed Medical Advisory Board.
SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics, a nbiosynthesis company focused on creating ethical and nenvironmentally-friendly products to improve mental health and increase nhealthspan, believes their partnership with atai Life Sciences will helpnto meet the growing unmet needs of patients with mental health nconditions.
SAN DIEGO--(BUSINESS WIRE)--CB Therapeutics is a leading biosynthesis company focused on the research and development of environmentally-friendly products to improve mental health, increase healthspan, and promote longevity.
SAN DIEGO--(BUSINESS WIRE)--CB Therapeutics Inc., the leading synthetic biology company focused on the development and biosynthetic production of existing and novel tryptamines and cannabinoids, is pleased to announce that it has closed an oversubscribed Series A funding round, filled entirely by re.Mind Capital, a fund launched by the psychedelics kingmaker, Christian Angermayer within Apeiron, his family office.
SAN DIEGO--(BUSINESS WIRE)--CB Therapeutics Inc., has successfully refined its in-house downstream processing, allowing for 99.6% pure CBC. a rare cannabinoid molecule found in trace quantities in cannabis and hemp. Using these patent-pending techniques, CB Therapeutics is able to drive down the cost of purification in parallel with increasing the purity to over 99%, considered a major breakthrough for any type of purification process.
SAN DIEGO--(BUSINESS WIRE)--CB Therapeutics, Inc. has achieved the first successful biosynthesis of DMT (N,N Dimethyltryptamine) and related tryptamine-based compounds in yeast and has filed a patent on their biosynthetic production process for DMT and related analogs. CB Therapeutics’ development of a DMT production process, and its patent application, closely follows the first biosynthetic production of psilocybin in yeast and the patent application for the process.
SAN DIEGO--(BUSINESS WIRE)--CB Therapeutics, Inc. has achieved the first successful biosynthesis of DMT (N,N Dimethyltryptamine) and related tryptamine-based compounds in yeast and has filed a patent on their biosynthetic production process for DMT and related analogs. CB Therapeutics’ development of a DMT production process, and its patent application, closely follows the first biosynthetic production of psilocybin in yeast and the patent application for the process.